New AI-based Technologies in Nuclear Medicine
New AI-based Technologies for Even Safer and More Precise Nuclear Medicine
Azienda USL Reggio Emilia - IRCCS
1,500 participants
Jul 30, 2021
OBSERVATIONAL
Conditions
Summary
The study aims to identify and predict radiopharmaceutical extravasation events using new semi-quantitative parameters and machine learning models. It involves dose rate measurements to develop metrics for real-time monitoring. It also investigates the correlation between extravasation and SUV correction in PET/CT diagnostics, providing an estimate of the correction factor necessary for accurate SUV evaluation in case of an extravasation event.
Eligibility
Inclusion Criteria1
- patients undergoing PET/CT scans or therapeutic treatments with radiopharmaceuticals labelled with alpha or beta emitting nuclides
Exclusion Criteria1
- patients whose clinical or psychological conditions do not allow for their involvement
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Acquisition of data during the infusion of PET radiotracers and the administration of α and β emitting radiopharmaceuticals for therapy.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07174089